JP2021523945A5 - - Google Patents

Info

Publication number
JP2021523945A5
JP2021523945A5 JP2021514456A JP2021514456A JP2021523945A5 JP 2021523945 A5 JP2021523945 A5 JP 2021523945A5 JP 2021514456 A JP2021514456 A JP 2021514456A JP 2021514456 A JP2021514456 A JP 2021514456A JP 2021523945 A5 JP2021523945 A5 JP 2021523945A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
composition according
optionally
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523945A (ja
JP7644000B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/050462 external-priority patent/WO2019218015A1/en
Publication of JP2021523945A publication Critical patent/JP2021523945A/ja
Publication of JP2021523945A5 publication Critical patent/JP2021523945A5/ja
Application granted granted Critical
Publication of JP7644000B2 publication Critical patent/JP7644000B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514456A 2018-05-15 2019-05-15 活性化剤 Active JP7644000B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901672 2018-05-15
AU2018901672A AU2018901672A0 (en) 2018-05-15 Activating Agents
PCT/AU2019/050462 WO2019218015A1 (en) 2018-05-15 2019-05-15 Activating agents

Publications (3)

Publication Number Publication Date
JP2021523945A JP2021523945A (ja) 2021-09-09
JP2021523945A5 true JP2021523945A5 (enExample) 2022-05-24
JP7644000B2 JP7644000B2 (ja) 2025-03-11

Family

ID=68539125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514456A Active JP7644000B2 (ja) 2018-05-15 2019-05-15 活性化剤

Country Status (8)

Country Link
US (2) US12134663B2 (enExample)
EP (1) EP3794015A4 (enExample)
JP (1) JP7644000B2 (enExample)
KR (1) KR20210021311A (enExample)
CN (1) CN112368293A (enExample)
AU (1) AU2019268411B2 (enExample)
CA (1) CA3100072A1 (enExample)
WO (1) WO2019218015A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7386852B2 (ja) 2018-05-15 2023-11-27 インテルク ペプチド セラピューティクス リミテッド ペプチド活性化剤
CN113166205A (zh) * 2018-11-30 2021-07-23 英特肽治疗有限公司 用于改善皮肤病状的多肽和方法
US20250262139A1 (en) * 2020-11-10 2025-08-21 Interk Peptide Therapeutics Limited Polypeptides and methods for improving skin conditions
KR20240044517A (ko) * 2021-08-20 2024-04-04 인터크 펩타이드 테라퓨틱스 리미티드 암 및 암 요법과 연관된 자가면역을 포함한 자가면역을 치료하기 위한 조성물 및 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226552B (it) 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Peptidi immunostimolanti.
US20030162956A1 (en) 1997-04-07 2003-08-28 Human Genome Sciences, Inc. Leukocyte regulatory factors 1 and 2
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
JP4458846B2 (ja) 2001-10-15 2010-04-28 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド invitroおよびinvivoにおけるDNA導入および遺伝子療法のためのベクターとしての完全なミニ細胞
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
CA2539914A1 (en) 2003-09-22 2005-04-07 Acidophil Llc Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2006029005A2 (en) 2004-09-02 2006-03-16 Oklahoma Medical Research Foundation Promoter substitution for immunoglobulin therapy
WO2006029981A1 (en) 2004-09-13 2006-03-23 Vib Vzw Abin-mediated protection against lung inflammatory disease
PT2229956E (pt) 2004-09-13 2013-07-31 Genzyme Corp Contruções multiméricas
WO2006031996A2 (en) 2004-09-14 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeting viruses using a modified sindbis glycoprotein
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションPurdue Research Foundation キナーゼ阻害薬およびその使用
CA2697896C (en) * 2007-09-18 2016-06-28 Green Peptide Co., Ltd. Ctl inducer composition
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
CA2744104C (en) * 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
JP2012518602A (ja) 2009-02-23 2012-08-16 インター−ケイ ピーティーワイ リミテッド 複数の細胞活性化経路の阻害
US9580474B2 (en) 2010-09-08 2017-02-28 The Johns Hopkins University Polyionic papilloma virus-like particle (VLP) vaccines
EP2720705A4 (en) 2011-06-16 2015-02-18 Jolla Inst Allergy Immunolog COMPOSITIONS, APPLICATIONS AND METHODS OF TREATING PKC-THETA PATHOLOGIES, UNWANTED IMMUNE REACTIONS AND DISEASES
WO2013033838A1 (en) 2011-09-09 2013-03-14 Pharmagap Inc. Liposomal formulations of cationic peptides and uses thereof
WO2013110120A1 (en) 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy
WO2015053338A1 (ja) * 2013-10-08 2015-04-16 学校法人東京理科大学 カチオン性ペプチドおよびそれを含む医薬組成物
JP6367600B2 (ja) 2014-04-18 2018-08-01 矢崎総業株式会社 コネクタ
EP3634978A1 (en) 2017-06-07 2020-04-15 Adrx, Inc. Tau aggregation inhibitors

Similar Documents

Publication Publication Date Title
JP2021523945A5 (enExample)
JP7360419B2 (ja) 安定化抗微生物性ペプチド
JP2014521684A5 (enExample)
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2005526833A5 (enExample)
FI3746467T3 (fi) Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö
RU2016110153A (ru) Новые пептиды и их аналоги для применения при лечении мукозита полости рта
JP2009534451A5 (enExample)
JP2021523946A5 (enExample)
JPWO2022202816A5 (enExample)
CN109265557A (zh) 一种齐考诺肽和tat肽的融合多肽在制备药物中的应用
CN109265558A (zh) 改进型齐考诺肽在制备药物中的应用
US12146005B2 (en) Compositions and methods for treatment of fungal infections
CN109232744A (zh) 改进型齐考诺肽
EP2990415B1 (en) Cyclic beta defensins analogs for the treatment of infections
US20180201647A1 (en) Peptoid
EP3423471A1 (en) Fusion respiratory syncytial virus inhibitors and use thereof
CN111247162B (zh) 多黏菌素类似物及其制备方法
JPWO2018038168A1 (ja) ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬
CN109232746A (zh) 一种齐考诺肽和tat肽的融合多肽
US12012440B2 (en) Compositions and methods for treatment of fungal infections
WO1997048725A1 (en) Novel peptides for prevention and treatment of infection
JP6578546B2 (ja) Lt阻害4価ペプチドおよびetec感染症治療薬
TW476650B (en) Use of a cytokine regulatory agent to treat rheumatoid arthritis
US7314867B2 (en) Pharmaceutical composition comprising a retro-iverso isomer peptide